Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.49 |
| ▸ | NOS2 | P35228 | 4/20 | 0.49 |
| ▸ | NOS3 | P29474 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL787716 | 0.98 | NOS1 (0.50) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL445763 | 0.90 | TACR1 (0.44) | NOS1NOS2NOS3TACR1 | |
| Hydrochloric Acid SCHEMBL787937 | 0.89 | TACR1 (0.43) | NOS1NOS2NOS3TACR1IDO1 | |
| SCHEMBL14492896 | 0.87 | TACR1 (0.50) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL788092 | 0.82 | TACR1 (0.40) | TACR1IDO1TSHRMAPK1 | |
| SCHEMBL30950869 | 0.82 | TACR1 (0.40) | TACR1IDO1TSHRMAPK1 | |
| Hydrochloric Acid SCHEMBL787855 | 0.81 | IDO1 (0.42) | NOS1NOS2NOS3TACR1IDO1 | |
| SCHEMBL10169147 | 0.81 | NOS1 (0.44) | NOS1NOS2NOS3TACR1TAAR1 | |
| SCHEMBL15077173 | 0.81 | TACR1 (0.46) | NOS1NOS2NOS3TACR1TAAR1 | |
| Hydrochloric Acid SCHEMBL5913029 | 0.81 | IDO1 (0.42) | NOS1NOS2NOS3TACR1IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | EXELIXIS, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| WO-2012037132-A1 | PHTALAZINE DERIVATIVES AS JAK1 INHIBITORS | EXELIXIS, INC. (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165440-A1 | JAK1 Inhibitors | JAK1, JAK2, JAK3 | NOS1 1852/4885NOS2 2443/4885NOS3 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.